MBX Biosciences develops peptide-based drug candidates for endocrine and metabolic disorders, including a lead treatment for a rare hormone disorder. It last closed at $53.10 on Nov 17, down 0.04% on the day. The average 12-month price target from 4 analysts is $103.00 (+94.0% from the last close), with a high of $150.00 and a low of $84.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).
Each firm's latest rating on MBX in the past 90 days
Average 12-month target
$103.00
▲ 94.0% upside
Based on 4 analysts who set a price target on MBX in the past 90 days. The average target is $103.00, with a high of $150.00 and a low of $84.00, compared with the last close of $53.10.
Low $84.00Avg $103.00High $150.00
Blue marker: last close $53.10
Highest target$150.00
Average target$103.00
Lowest target$84.00
Latest rating changes
HC Wainwright & Co.Initiated
Nov 12Buy$90
StifelMaintained
Oct 12Buy$84
GuggenheimMaintained
Oct 2Buy$150
JP MorganReinstated
Aug 21Buy$88
Truist SecuritiesMaintained
Aug 10Buy$88
Date
Firm
Action
Rating
Price target
Nov 12
HC Wainwright & Co.
Initiated
Buy
$90
Oct 12
Stifel
Maintained
Buy
$84
Oct 2
Guggenheim
Maintained
Buy
$150
Aug 21
JP Morgan
Reinstated
Buy
$88
Aug 10
Truist Securities
Maintained
Buy
$88
Loading…
Technical Analysis
MBX · as of the Nov 17 close · updated after every close
Moving sideways
The stock is 0% below its 20 day and 4% below its 50 day average. It is 12% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 48). The nearest support is the swing low (Jul 14) at $52.51, and the nearest resistance the 20 day average at $53.36.
Short trendNeutral
Long trendBullish
MomentumImproving
StretchNormal
VolatilityNormal, 6.9%/day
Key levels
$72.6452 week high+36.8%
$59.31100 day average+11.7%
$56.20Swing high (Oct 21)+5.8%
$55.4150 day average+4.4%
$54.05Pivot R1+1.8%
$53.3620 day average+0.5%
$53.10Last close
$52.51Swing low (Jul 14)−1.1%
$52.26Pivot−1.6%
$51.30Pivot S1−3.4%
$46.48200 day average−12.5%
$24.6852 week low−53.5%
Indicators
RSI (14)
47.86
Middle of its range
Neutral
MACD
-0.11
Above its signal line
Bullish
Stochastic
59.3
Middle of its range
Neutral
ADX (14)
13.4
No clear trend
Williams %R
-49.5
Oversold below −80, overbought above −20
Neutral
CCI (20)
-39.3
Oversold below −100, overbought above 100
Neutral
Rate of change
−3.5%
Change over 10 sessions
Bearish
ATR (14)
$3.65
Typical daily range, 6.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
Rising
Short trendBullish
Long trendNot enough history
MomentumFading
StretchNormal
VolatilityLow, 14.1%/day
Key levels
$72.6452 week high+36.8%
$59.31100 day average+11.7%
$56.20Swing high (Oct 21)+5.8%
$55.4150 day average+4.4%
$54.05Pivot R1+1.8%
$53.3620 day average+0.5%
$53.10Last close
$52.51Swing low (Jul 14)−1.1%
$52.26Pivot−1.6%
$51.30Pivot S1−3.4%
$46.48200 day average−12.5%
$24.6852 week low−53.5%
Indicators
RSI (14)
51.03
Middle of its range
Neutral
MACD
2.33
Below its signal line
Bearish
Stochastic
26.0
Middle of its range
Neutral
ADX (14)
35.3
Trending up
Williams %R
-75.0
Oversold below −80, overbought above −20
Neutral
CCI (20)
-78.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−10.0%
Change over 10 sessions
Bearish
ATR (14)
$7.50
Typical daily range, 14.1% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200–
What happened before, for MBX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how MBX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90D
No whale options trades in MBX in the last 90 days.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MBX is in one of them and how their past MBX trades turned out.
MBX Biosciences is a biopharmaceutical company based in Carmel, Indiana, that develops peptide medicines for hormone and metabolic conditions. Its candidates are built on a proprietary platform designed to give peptides longer action and steadier levels in the body, so they can be taken less often. The lead candidate targets chronic hypoparathyroidism, a rare hormone disorder. The company is also developing treatments for obesity and for low blood sugar after weight loss surgery. Its candidates are still in development, and its intended users are patients with these conditions.